Sverige - svensk - Läkemedelsverket (Medical Products Agency)

alpharma as - lisinoprildihydrat - tablett - 2,5 mg - lisinoprildihydrat 2,723 mg aktiv substans; mannitol hjälpämne - lisinopril

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

alpharma as - lisinoprildihydrat - tablett - 20 mg - mannitol hjälpämne; lisinoprildihydrat 21,78 mg aktiv substans - lisinopril

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

alpharma as - lisinoprildihydrat - tablett - 5 mg - mannitol hjälpämne; lisinoprildihydrat 5,445 mg aktiv substans - lisinopril

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

alpharma aps - mirtazapin - filmdragerad tablett - 30 mg - mirtazapin 30 mg aktiv substans; laktosmonohydrat hjälpämne - mirtazapin

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

alpharma aps - mirtazapin - filmdragerad tablett - 45 mg - laktosmonohydrat hjälpämne; mirtazapin 45 mg aktiv substans - mirtazapin

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

alpharma as - paroxetinhydroklorid (vattenfri) - filmdragerad tablett - 20 mg - sojalecitin hjälpämne; mannitol hjälpämne; paroxetinhydroklorid (vattenfri) 22,22 mg aktiv substans - paroxetin

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

alpharma as - sertralinhydroklorid - filmdragerad tablett - 100 mg - propylenglykol hjälpämne; sertralinhydroklorid 111,9 mg aktiv substans - sertralin

Sverige - svensk - Läkemedelsverket (Medical Products Agency)

alpharma as - sertralinhydroklorid - filmdragerad tablett - 50 mg - sertralinhydroklorid 55,95 mg aktiv substans; propylenglykol hjälpämne - sertralin

Den Europæiske Union - svensk - EMA (European Medicines Agency)

allergan pharmaceuticals international ltd - bukspottkörtelpulver - exokrin pankreatisk insufficiens - digestives, inkl. enzymer - behandling av pankreatisk enzymbehandling vid exokrin pankreasinsufficiens på grund av cystisk fibros eller andra tillstånd (e. kronisk pankreatit, post-pankreatektomi eller bukspottskörtelcancer). enzepi anges i spädbarn, barn, ungdomar och vuxna.

Den Europæiske Union - svensk - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastiska medel - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.